---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-030495"
form_type: "8-K"
ticker: "GRAL"
cik: "0001699031"
company_name: "GRAIL, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:26:42.121001+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# GRAIL Q1 2026: revenue $40.8M (up 28%), Galleri volume 56k+ (up 50%), net loss $93.2M

## Summary
- Total revenue $40.8M (+28% YoY); Galleri revenue $39.8M (+37%); test volume >56,000 (+50%).
- Net loss $93.2M, improved $13.0M (12%) vs Q1 2025; adjusted EBITDA $(79.9)M, improved 19%.
- Adjusted gross profit $19.7M (+38% YoY); cash & equivalents $823.1M.
- Plans to integrate Galleri into Epic EHR; new NHS-Galleri and PATHFINDER 2 data at ASCO 2026.

## SEC filing metadata
- accession: 0001628280-26-030495
- form_type: 8-K
- ticker: GRAL
- cik: 0001699031
- company_name: GRAIL, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699031/000162828026030495/0001628280-26-030495-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699031/000162828026030495/gral-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-030495
- JSON: https://secwatch.observer/filing/0001628280-26-030495.json
- Plain text: https://secwatch.observer/filing/0001628280-26-030495.txt

## Source-grounded claims
- claim_id: 87177db9e3945b660a868b670ad5c4e8b39803b4
  claim: GRAIL, Inc. reported first quarter ended March 31, 2026 results: revenue $40.8 million, net income $(93.2) million.
  evidence_excerpt: GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter of 2026. Total revenue in the first quarter grew 28% year over year to $40.8 million, and Galleri revenue grew 37% year-over-year to $39.8 million. Galleri test volume for the quarter grew 50% year-over-year to more than 56,000. Net loss for the quarter was $93.2 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699031/000162828026030495/0001628280-26-030495-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.